Professor Vijay Kumar

MSc (Med), PhD
Clinical Professor
USYD. Principal Radiopharmaceutical Scientist, Department of Nuclear Medicine, Westmead Hospital and The Children's Hospital.Worked at International Atomic Energy Agency, Vienna (2010), as Consultant Scientific Expert

Telephone 02 98456533
Fax 02 98915385

Map

Biographical details

Research Interest: Primarily involved in designing radiolabelled radiopharmaceuticals for evaluation in pre-clinical studies in an animal model and then using them in patient studies in a clinical setting. We have developed Ga-68 labelled PET-agents (Positron emitting isotopes) for imaging neuro-endocrine tumours, prostate cancer and bacterial infections. We have developed F18 FET (Fluoroethyl tyrosine) for imaging brain tumours and adopted the technology in automated synthesis.

Research interests

Research Interest:

Primarily involved in designing radiolabelled radiopharmaceuticals for evaluation in pre-clinical studies in an animal model and then using them in patient studies in a clinical setting.

(1) We have developed Ga-68 labelled PET-agents (Positron emitting isotopes) for imaging neuro-endocrine tumours, prostate cancer and bacterial infections.

(2) We have developed F18 FET (Fluoroethyl tyrosine) for imaging brain tumours and adopted the technology in automated synthesis.

(3) We have developed 99mTc-labelled Glucosamine for imaging arthritis

(4) Developed Ga-68 labelled Citrate, Ga-68 UBI for imaging infection

Teaching and supervision

Currently teaching Basic Science in Nuclear Medcine for the following faculties:

1. Registrars in Nuclear Medicine - Conducted by Australian Association of Nuclear Medicine Physicians

2. Registrars in Radiology: Conducted by Australian Radiological Society

3. Curriculum advisor and lecturer, “Foundation PET/CT course” run by Research Institute for Asia and the Pacific – University of Sydney Program for Asian Nuclear Medicine technologists in Sydney, September 2013.

Current projects

1. We have developed 99mTc-labelled glucosamine for imaging arthritis. Our preliminary studies were to standardise the technique of synthsising the agent and evaluated its utility in imaging arthritis in an adjuvent-induced arthritis in an animal model.

The 99mTc-Glucosamine is successfully used in patient studies for imaging arthritis, osteo-arthritis, rheumatoid arthritis etc. More than 300 patients were studied using this agent.

2. We have developed Ga-68 labelled DOTA-TATE (DOTA-Octrotide) for imaging neuroendocrine tumours in patients since 2009. We are one of the first centres in Australia to introduce this technology. We studied more than 300-400 patients per year in the clinical settings.

3. We have developed Ga-68 labelled PSMA (Prostate Specific Membrane Antigen) for imaging prostate cancer. It is clincally used in our department and more than 100 pateitns are studied per annum. This is the superior imaging agent for prostate cancer compared to other modality (eg. CT/MRI etc).

4. We have developed Ga-68 labelled infection imaging agents. Ga-68 Citrate, Ga-68 Apotransferrin and Ga-68UBI (Ubiquicidin). The first 2 agents are in clinical use and the last agent (Ga-68 UBI) is currently being evaluated in pre-clinical studies.

Associations

(1) President of ANZSNM, Australian and New Zealand Society of Nuclear Medicine (2014-2016)

(2) Treasurer and Governing Council Member of WFNMB (World Federation of Nuclear Medicine & Biology) - 2014-2018

(3) Member of Board of Directors at ISORBE (International Society of Radiolabelled Blood Elements)

(4). Associated with International Atomic Energy Agency, Vienna for CRP (Coordinated Research Project) on Development of Cu-64 labelled Radiopharmaceuticals for theranostic imaging of neuroendocrine tumours. Project Period: 2016-2019

Awards and honours

ANSTO Award (2014): I won the Australian Nuclear Science and Technology Award was in 2014 conferred by ANZSNM (Australia and NZ Society of Nuclear Medicine). This award was in recognition of research efforts in the advancement of Nuclear Medicne practice.

Life-time Achievement Award: Conferred by Society of Nuclear Medicine, India for contribution to research and education.

ANSTO Award (2007): I won the Australian Nuclear Science and Technology Award was in 2007 conferred by ANZSNM (Australia and NZ Society of Nuclear Medicine). This award was in recognition of research efforts in the advancement of Nuclear Medicne practice.

(1) President of ANZSNM, Australian and New Zealand Society of Nuclear Medicine (2014-2016)

(2) Treasurer and Governing Council Member of WFNMB (World Federation of Nuclear Medicine & Biology) - 2014-2018

(3) Member of Board of Directors at ISORBE (International Society of Radiolabelled Blood Elements)

International links

Austria

(International Atomic Energy Agency (IAEA), Vienna.) Worked at IAEA as a Consultant Radiopharmaceutical Science Expert under Special Services Agreement, at Department of Nuclear Science Applications, in 2010. Initiated the Co-ordinated Research Project(CRP) on "Development of Ga-68 based PET-Radiopharmaceuticals for Management of Cancer and other Chronic Diseases".

Austria

(International Atomic Energy Agency, Vienna) Co-ordinated Research Project "Research Coordination meeting on Cu-64 Radiopharmaceuticals for Theranostic Applications". Designing a work plan for developing and evaluating radiopharmaceuticals for diagnosis and therapy of neuroendocrine tumours and prostate cancer.

Germany

(Institut fuer Kernchemie Johannes Gutenberg-Universitaet Mainz) Develop scientific projects on the preparation and evaluation of 68Ga-labelled Radiopharmaceuticals for PET-imaging.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Kumar, V., Boddeti, D. (2013). 68 Ga-Radiopharmaceuticals for PET lmaging of Infection and Inflammation. In Richard P. Baum and Frank Rosch (Eds.), Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalised Diagnosis and Treatment, (pp. 189-219). New York: Springer.
  • Kumar, V., Baker, R., Barnes, R. (2004). Fundamentals Of Radiochemistry. Radiopharmacy. In Peter Ell, Sam Gambhir (Eds.), Nuclear Medicine in Clinical Diagnosis and Treatment, (pp. 1721-1736). Edinburgh, UK: Churchill Livingstone.

Journals

  • Vanniasinghe, A., Manolios, N., Schibeci, S., Lakhiani, C., Kamali-Sarvestani, E., Sharma, R., Kumar, V., Moghaddam, M., Ali, M., Bender, V. (2014). Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis. Clinical Immunology, 151(1), 43-54. [More Information]
  • Angelides, S., El-Mashaleh, M., Anagnostou, M., Howe, G., Spencer, D., Kumar, V., Manolios, N. (2014). The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease: a screening experience. Nuclear Medicine Communications, 35(6), 655-668. [More Information]
  • Kumar, V., Boddeti, D., Evans, S., Angelides, S. (2012). (68)Ga-Citrate-PET for Diagnostic Imaging of Infection in Rats and for Intra-Abdominal Infection in a Patient. Current Radiopharmaceuticals, 5(1), 71-75. [More Information]
  • Ali, M., Vanniasinghe, A., Kumar, V., Barnett, R., Alberto, R., Manolios, N. (2011). 99mTc-technetium labeling of antiarthritic peptides to evaluate homing and biodistribution at inflamed joints. Nuclear Medicine and Biology, 38(5), 751-756. [More Information]
  • Kumar, V., Boddeti, D., Evans, S., Roesch, F., Howman-Giles, R. (2011). Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection. Nuclear Medicine and Biology, 38(3), 393-398. [More Information]
  • Wong, E., Kumar, V., Howman-Giles, R., Vanderheyden, J. (2008). Imaging of Therapy-Induced Apoptosis Using 99mTc-HYNIC-Annexin V in Thymoma Tumor-Bearing Mice. Cancer Biotherapy and Radiopharmaceuticals, 23(6), 1-11. [More Information]
  • Kumar, V., Kumar, D., Howman-Giles, R., Little, D. (2007). Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging? Nuclear Medicine Communications, 28(2), 101-107. [More Information]
  • Kumar, V., Kumar, D., Howman-Giles, R., Little, D. (2007). Is Tc-99m-labelled pamidronate a better agent than Tc-99m-medronate for bone imaging? Nuclear Medicine Communications, 28(2), 101-107.
  • Kumar, V., Ali, M., Angelides, S., Manolios, N. (2007). Synthesis and characterization of 99mTc-Glucosamine & 99mTc-His-CP and evaluation of their utility in imaging inflammatory arthritis. Australian and New Zealand Nuclear Medicine, 38(3), 10-13.
  • Kumar, D., Kumar, V., Little, D., Howman-Giles, R., Wong, E., Ali, S. (2006). Evaluation of biodistribution by local versus systemic administration of (99m)Tc-labeled pamidronate. Journal of orthopaedic science, 11(5), 512-520. [More Information]
  • Kumar, V. (2006). New radiopharmaceuticals for diagnosis and treatment. World Journal of Nuclear Medicine, 5, 237-240.
  • Kumar, V. (2005). Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 49(4), 325-338. [More Information]

2014

  • Vanniasinghe, A., Manolios, N., Schibeci, S., Lakhiani, C., Kamali-Sarvestani, E., Sharma, R., Kumar, V., Moghaddam, M., Ali, M., Bender, V. (2014). Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis. Clinical Immunology, 151(1), 43-54. [More Information]
  • Angelides, S., El-Mashaleh, M., Anagnostou, M., Howe, G., Spencer, D., Kumar, V., Manolios, N. (2014). The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease: a screening experience. Nuclear Medicine Communications, 35(6), 655-668. [More Information]

2013

  • Kumar, V., Boddeti, D. (2013). 68 Ga-Radiopharmaceuticals for PET lmaging of Infection and Inflammation. In Richard P. Baum and Frank Rosch (Eds.), Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalised Diagnosis and Treatment, (pp. 189-219). New York: Springer.

2012

  • Kumar, V., Boddeti, D., Evans, S., Angelides, S. (2012). (68)Ga-Citrate-PET for Diagnostic Imaging of Infection in Rats and for Intra-Abdominal Infection in a Patient. Current Radiopharmaceuticals, 5(1), 71-75. [More Information]

2011

  • Ali, M., Vanniasinghe, A., Kumar, V., Barnett, R., Alberto, R., Manolios, N. (2011). 99mTc-technetium labeling of antiarthritic peptides to evaluate homing and biodistribution at inflamed joints. Nuclear Medicine and Biology, 38(5), 751-756. [More Information]
  • Kumar, V., Boddeti, D., Evans, S., Roesch, F., Howman-Giles, R. (2011). Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection. Nuclear Medicine and Biology, 38(3), 393-398. [More Information]

2008

  • Wong, E., Kumar, V., Howman-Giles, R., Vanderheyden, J. (2008). Imaging of Therapy-Induced Apoptosis Using 99mTc-HYNIC-Annexin V in Thymoma Tumor-Bearing Mice. Cancer Biotherapy and Radiopharmaceuticals, 23(6), 1-11. [More Information]

2007

  • Kumar, V., Kumar, D., Howman-Giles, R., Little, D. (2007). Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging? Nuclear Medicine Communications, 28(2), 101-107. [More Information]
  • Kumar, V., Kumar, D., Howman-Giles, R., Little, D. (2007). Is Tc-99m-labelled pamidronate a better agent than Tc-99m-medronate for bone imaging? Nuclear Medicine Communications, 28(2), 101-107.
  • Kumar, V., Ali, M., Angelides, S., Manolios, N. (2007). Synthesis and characterization of 99mTc-Glucosamine & 99mTc-His-CP and evaluation of their utility in imaging inflammatory arthritis. Australian and New Zealand Nuclear Medicine, 38(3), 10-13.

2006

  • Kumar, D., Kumar, V., Little, D., Howman-Giles, R., Wong, E., Ali, S. (2006). Evaluation of biodistribution by local versus systemic administration of (99m)Tc-labeled pamidronate. Journal of orthopaedic science, 11(5), 512-520. [More Information]
  • Kumar, V. (2006). New radiopharmaceuticals for diagnosis and treatment. World Journal of Nuclear Medicine, 5, 237-240.

2005

  • Kumar, V. (2005). Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 49(4), 325-338. [More Information]

2004

  • Kumar, V., Baker, R., Barnes, R. (2004). Fundamentals Of Radiochemistry. Radiopharmacy. In Peter Ell, Sam Gambhir (Eds.), Nuclear Medicine in Clinical Diagnosis and Treatment, (pp. 1721-1736). Edinburgh, UK: Churchill Livingstone.

To update your profile click here. For support on your academic profile contact .